Reported about 22 hours ago
GSK Plc, lagging in performance among major European pharmaceutical firms, is facing scrutiny from analysts and the possibility of renewed interest from activist investors as key drug patents expire and vaccine sales decline. Despite a recent uptick in sales forecasts, the company's share price continues to struggle, prompting suggestions for potential mergers, focus on vaccines, and better shareholder returns. Ongoing litigation and the need for genuine operational improvement have left GSK's appeal as an investment under question, although its dividend yield remains attractive.
Source: YAHOO